Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Which factors predict mortality in advanced HCC?
A study has found the high bilirubin, pretreatment hypoalbuminemia, and biochemical tests indicative of hepatic or renal dysfunctions are independently associated with short-term mortality in patients with advanced hepatocellular cancer (HCC) receiving atezolizumab and bevacizumab (Atezo/Bev).
Which factors predict mortality in advanced HCC?
01 Mar 2024
Nivolumab plus ipilimumab superior to sunitinib in advanced RCC
First-line treatment with nivolumab plus ipilimumab (NIVO+IPI) results in better survival and response benefits in patients with advanced renal cell carcinoma (aRCC) when compared with sunitinib (SUN), as shown by long-term follow-up data from the CheckMate 214 trial.
Nivolumab plus ipilimumab superior to sunitinib in advanced RCC
01 Mar 2024
Pembrolizumab plus lenvatinib effective against nonclear cell RCC
Pembrolizumab (pembro) plus lenvatinib (lenva) provides durable antitumour activity in patients with advanced nonclear cell renal cell carcinoma (nccRCC) and has a manageable safety profile, according to the results of the phase II KEYNOTE-B61 study.
Pembrolizumab plus lenvatinib effective against nonclear cell RCC
29 Feb 2024
Cilostazol, ticagrelor more cost-effective than standard therapy for acute ischaemic stroke
Use of CYP2C19 genotype-guided antiplatelet therapy with cilostazol or ticagrelor as a substitute to clopidogrel is more cost-effective than conventional antiplatelet therapy for patients with acute minor ischaemic stroke and high-risk transient ischaemic attack, suggests a China study.